| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC23567 | JNJ303 Featured | JNJ303 is a potent, specific delayed rectifier potassium current I(Ks) blocker with IC50 of 64 nM, shows no effects on other cardiac channels (IC50=3.3, >10, 11.1 and 12.6 uM for Na, ICa, Ito and IKr currents). |
|
| DC22405 | JNJ-37822681 | JNJ-37822681 is a potent, specific and fast-dissociating dopamine D2 antagonist with Ki of 158 nM. |
|
| DC8521 | JNJ-38158471 | JNJ-38158471(KDR) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50=40nM. It also inhibits closely related tyrosine kinases, Ret (180nM) and Kit (500nM). It has no significant activity (>1 microM) against VEGFR-1 and VEGF |
|
| DC21440 | JNJ-38877618 | JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively. |
|
| DC21174 | JNJ-38893777 | JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain.. |
|
| DC21175 | JNJ-38893777 sulfate | JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain.. |
|
| DC22738 | JNJ-39393406 | JNJ-39393406 is a potent, selective positive allosteric α7 nAChR modulator, potentiates a 100 μM choline-induced rise in intracellular calcium mediated by human α7 channels expressed in GH4C1 cells with EC50 of 660 nM. |
|
| DC21176 | JNJ-39729209 | JNJ-39729209 is a potent, selective TRPV1 antagonist with binding pKi of 7.8 and 7.9 for human and rat TRPV1, respectively. |
|
| DC22750 | JNJ-39933673 hemihydrate | JNJ-39933673 hemihydrate is a potent, selective SGLT2 inhibitor.. |
|
| DC22751 | JNJ-39933673 | JNJ-39933673 is a potent, selective SGLT2 inhibitor.. |
|
| DC22683 | JNJ-40279486 | JNJ-40279486 is a potent, selective histamine H4 receptor antagonist with Ki of 9.4 nM (hH4), demonstrates acceptable pharmacokinetic profile and efficacy in mouse model of inflammation.. |
|
| DC21178 | JNJ-40413269 | JNJ-40413269 is a potent, selective, blood brain barrier (BBB) penetrant FAAH inhibitor with IC50 of 5.3 and 6.3 nM for hFAAH and rFAAH, respectively. |
|
| DC22757 | JNJ-42314415 | JNJ-42314415(JNJ42314415) is a potent, selective, centrally active phosphodiesterase 10A (PDE10A) inhibitor with Ki of 35 nM for human recombinant PDE10A. |
|
| DC21169 | JNJ-42905343 | JNJ-42905343 is a potent, selective, orally active prolyl hydroxylase (PHD) inhibitor with pKi of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3 respectively. |
|
| DC21180 | JNJ-47965567 Featured | JNJ-47965567 is a potent, selective, centrally permeable P2X7 receptor antagonist with pKi of 7.9 and 8.7 for human and rat P2X7, respectively. |
|
| DC21597 | JNJ-49095397 | JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively. |
|
| DC23679 | JNJ-4929821 | JNJ-4929821 is a potent, reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 8 nM.. |
|
| DC12166 | JNJ-5207852 Featured | JNJ-5207852 is a selective and potent histamine H3 receptor (H3R) antagonist, with pKis of 8.9, 9.24 for rat and human H3R, respectively. |
|
| DC21181 | JNJ-5234801 | JNJ-5234801 is an atypical anxiolytic targeting 5-HT2 receptor, has demonstrated oral activity in animal models of anxiety.. |
|
| DC21170 | JNJ525 | JNJ525 is a small molecule inhibitor of TNFα that prevents the formation of TNFα complexes with TNFR1 and TNFR2 with IC50 of 1.2 uM and 1.1 uM in the TR-FRET assay, respectively.. |
|
| DC21182 | JNJ-53718678 Featured | JNJ-53718678 (JNJ53718678, JNJ-678) is a potent (Kd=7.4 nM), small-molecule inhibitor of the F-glycoprotein-mediated complex membrane fusion process of the RSV. |
|
| DC12271 | JNJ-54175446 Featured | JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC50s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively. |
|
| DC21183 | JNJ-55308942 | JNJ-55308942 is a novel highly potent P2X7 antagonist with Ki of 1.0 and 6.5 nM for rat and human hP2X7, demonstrates significant activity against a panel of related P2X receptors (P2X1, P2X2, P2X3, P2X2/3, and P2X4. |
|
| DC11229 | JNJ-55511118 | JNJ-55511118 (JNJ55511118) is a selective, orally available AMPA receptor containing TARP-γ8 negative modulator with Ki of 26 nM, displays no significant activity against other TARP-less AMPARs and AMPARs coexpressed with other TARPs or CNIH2. |
|
| DC23273 | JPC-3210 | JPC-3210 is a potent antimalarial agent with IC50 of 2.5-19 nM, remains activity against multidrug-resistant Plasmodium falciparum lines with little cytotoxicity in mammalian cell lines. |
|
| DC22516 | Unii-cedo9qxyzk Featured | JPH203 (KYT-0353) is a potent, selective L-type amino acid transporter 1 (LAT1, SLC7A5) inhibitor with IC50 of 60 nM (leucine uptake inhibition), but not LAT2. |
|
| DC11080 | JPI-289 | JPI-289 (JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM. |
|
| DC21911 | JQ1-VHL-PROTAC | JQ1-VHL-PROTAC is a novel PROTAC synthesis.. |
|
| DC12191 | JQ-35-(S) Featured | JQ-35, (S)- is an inhibitor of the Bromodomain and Extra-Terminal (BET) family bromodomain-containing proteins with potential antineoplastic activity. |
|
| DC12640 | JSF-4088 | JSF-4088 (JSF4088) is a novel antitubercular agent with potent in vitro antitubercular potency (MIC=19 nM), with no significant Vero cell cytotoxicity (CC50 >120 uM).. |
|
